KR20240011255A - 과다운동성 운동 장애의 치료를 위한 vmat2 억제제 - Google Patents

과다운동성 운동 장애의 치료를 위한 vmat2 억제제 Download PDF

Info

Publication number
KR20240011255A
KR20240011255A KR1020247001490A KR20247001490A KR20240011255A KR 20240011255 A KR20240011255 A KR 20240011255A KR 1020247001490 A KR1020247001490 A KR 1020247001490A KR 20247001490 A KR20247001490 A KR 20247001490A KR 20240011255 A KR20240011255 A KR 20240011255A
Authority
KR
South Korea
Prior art keywords
htbz
dimethoxy
isobutyl
pyrido
isoquinolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020247001490A
Other languages
English (en)
Korean (ko)
Inventor
크리스토퍼 에프. 오브라이언
Original Assignee
뉴로크린 바이오사이언시즈 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 뉴로크린 바이오사이언시즈 인코퍼레이티드 filed Critical 뉴로크린 바이오사이언시즈 인코퍼레이티드
Priority to KR1020257005033A priority Critical patent/KR20250029267A/ko
Publication of KR20240011255A publication Critical patent/KR20240011255A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
KR1020247001490A 2014-05-06 2015-05-06 과다운동성 운동 장애의 치료를 위한 vmat2 억제제 Ceased KR20240011255A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257005033A KR20250029267A (ko) 2014-05-06 2015-05-06 과다운동성 운동 장애의 치료를 위한 vmat2 억제제

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461989240P 2014-05-06 2014-05-06
US61/989,240 2014-05-06
PCT/US2015/029519 WO2015171802A1 (en) 2014-05-06 2015-05-06 Vmat2 inhibitors for the treatment of hyperkinetic movement disorders
KR1020227034399A KR20220140647A (ko) 2014-05-06 2015-05-06 과다운동성 운동 장애의 치료를 위한 vmat2 억제제

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020227034399A Division KR20220140647A (ko) 2014-05-06 2015-05-06 과다운동성 운동 장애의 치료를 위한 vmat2 억제제

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257005033A Division KR20250029267A (ko) 2014-05-06 2015-05-06 과다운동성 운동 장애의 치료를 위한 vmat2 억제제

Publications (1)

Publication Number Publication Date
KR20240011255A true KR20240011255A (ko) 2024-01-25

Family

ID=53264772

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020247001490A Ceased KR20240011255A (ko) 2014-05-06 2015-05-06 과다운동성 운동 장애의 치료를 위한 vmat2 억제제
KR1020167033765A Ceased KR20160147044A (ko) 2014-05-06 2015-05-06 과다운동성 운동 장애의 치료를 위한 vmat2 억제제
KR1020257005033A Pending KR20250029267A (ko) 2014-05-06 2015-05-06 과다운동성 운동 장애의 치료를 위한 vmat2 억제제
KR1020227034399A Ceased KR20220140647A (ko) 2014-05-06 2015-05-06 과다운동성 운동 장애의 치료를 위한 vmat2 억제제
KR1020207032879A Ceased KR20200133003A (ko) 2014-05-06 2015-05-06 과다운동성 운동 장애의 치료를 위한 vmat2 억제제

Family Applications After (4)

Application Number Title Priority Date Filing Date
KR1020167033765A Ceased KR20160147044A (ko) 2014-05-06 2015-05-06 과다운동성 운동 장애의 치료를 위한 vmat2 억제제
KR1020257005033A Pending KR20250029267A (ko) 2014-05-06 2015-05-06 과다운동성 운동 장애의 치료를 위한 vmat2 억제제
KR1020227034399A Ceased KR20220140647A (ko) 2014-05-06 2015-05-06 과다운동성 운동 장애의 치료를 위한 vmat2 억제제
KR1020207032879A Ceased KR20200133003A (ko) 2014-05-06 2015-05-06 과다운동성 운동 장애의 치료를 위한 vmat2 억제제

Country Status (24)

Country Link
US (3) US20170071932A1 (enExample)
EP (3) EP3936130B1 (enExample)
JP (4) JP6635945B2 (enExample)
KR (5) KR20240011255A (enExample)
CN (3) CN112741835A (enExample)
AU (1) AU2015256012B2 (enExample)
CA (1) CA2947736C (enExample)
CY (1) CY1125058T1 (enExample)
DK (2) DK3139925T3 (enExample)
ES (2) ES2904526T3 (enExample)
FI (1) FI3936130T3 (enExample)
HR (2) HRP20240459T1 (enExample)
HU (2) HUE057839T2 (enExample)
IL (1) IL248745B (enExample)
LT (2) LT3936130T (enExample)
MX (1) MX387625B (enExample)
NZ (1) NZ725826A (enExample)
PL (2) PL3139925T3 (enExample)
PT (2) PT3936130T (enExample)
RS (2) RS65359B1 (enExample)
RU (1) RU2753740C2 (enExample)
SI (2) SI3139925T1 (enExample)
SM (2) SMT202200193T1 (enExample)
WO (1) WO2015171802A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115304596A (zh) * 2015-10-30 2022-11-08 纽罗克里生物科学有限公司 Valbenazine盐及其多晶形物
SI3394057T1 (sl) 2015-12-23 2022-06-30 Neurocrine Biosciences, Inc. Sintetičen postopek za pripravo (S)-(2R,3R,11bR)-3-izobutil-9,10-dimetoksi-2,3,4,6,7,11b-heksahidro-1H- pirido(2,1,-a)izokinolin-2-il 2-amino-3-metilbutanoat di(4-metilbenzensulfonata)
US10442800B2 (en) 2016-06-29 2019-10-15 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal forms of NBI-98854, preparation method and use thereof
WO2018102673A1 (en) * 2016-12-02 2018-06-07 Neurocrine Biosciences, Inc. Use of valbenazine for treating schizophrenia or schizoaffective disorder
WO2018130345A1 (en) 2017-01-10 2018-07-19 Sandoz Ag Crystalline valbenazine free base
MY199695A (en) 2017-01-27 2023-11-18 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
WO2018153632A1 (en) 2017-02-27 2018-08-30 Sandoz Ag Crystalline forms of valbenazine salts
WO2018164996A1 (en) * 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
GB201705305D0 (en) * 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
CN110691596A (zh) * 2017-04-01 2020-01-14 阿德普蒂奥制药有限公司 药物组合物
US20190111035A1 (en) * 2017-04-01 2019-04-18 Adeptio Pharmaceuticals Limited Pharmaceutical compositions
GB201705306D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705302D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
CA3057543A1 (en) * 2017-04-01 2018-10-04 Adeptio Pharmaceuticals Limited (+)-alpha-dihydrotetrabenazine for use in the treatment a movement disorder
GB201705304D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705303D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
WO2018200605A1 (en) * 2017-04-26 2018-11-01 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
DK3684333T3 (da) 2017-09-21 2025-05-12 Neurocrine Biosciences Inc Valbenazin-formulering med høj dosis og sammensætninger, fremgangsmåder og kits relateret hertil
US20200230127A1 (en) 2017-10-10 2020-07-23 Neurocrine Biosciences, Inc. Methods for the Administration of Certain VMAT2 Inhibitors
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
RU2020114598A (ru) 2017-11-08 2021-12-09 Фореси Фармасьютикалс Ко., Лтд. Сложные эфиры дигидротетрабеназина
JP7212958B2 (ja) 2017-12-26 2023-01-26 ▲蘇▼州科睿思制▲葯▼有限公司 バルベナジントシル酸塩の結晶形及びその製造方法並びに用途
AU2019261403B2 (en) 2018-04-25 2025-05-15 Shinkei Therapeutics, Inc. Tetrabenazine transdermal delivery device
GB201808464D0 (en) 2018-05-23 2018-07-11 Adeptio Pharmaceuticals Ltd Pharmaceutical compounds for use in treating huntington's disease
MX2020013004A (es) 2018-06-14 2021-02-17 Neurocrine Biosciences Inc Compuestos inhibidores del transportador de monoamina 2 (vmat2), composiciones, y metodos relacionados con los mismos.
BR112021000019A2 (pt) 2018-08-15 2021-04-06 Neurocrine Biosciences Inc. Métodos para administração de certos inibidores de vmat2
EP3860599B1 (en) 2018-10-04 2024-05-15 Adeptio Pharmaceuticals Limited (+)-alpha-dihydrotetrabenazine dosage regimen for treating movement disorders
IL321020A (en) * 2019-05-09 2025-07-01 Neurocrine Biosciences Inc Methods of administering certain vmat2 inhibitors
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2081929B1 (en) * 2006-11-08 2013-01-09 Neurocrine Biosciences, Inc. Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto
EP2083744A4 (en) * 2006-11-09 2013-08-28 Univ New York DEGRADED GLASS / ZIRCONIUM / GLASS STRUCTURES FOR DAMAGE-RESISTANT DENTAL AND ORTHOPEDIC CERAMIC PROSTHESES
WO2011019956A2 (en) * 2009-08-12 2011-02-17 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
EP3345905B1 (en) 2008-09-18 2021-09-01 Auspex Pharmaceuticals, Inc. Deuterated benzoquinolizine derivatives as inhibitors of vesicular monoamine transporter 2
WO2011153157A2 (en) * 2010-06-01 2011-12-08 Auspex Pharmaceutical, Inc. Benzoquinolone inhibitors of vmat2
EP2897615A4 (en) * 2012-09-18 2016-04-27 Auspex Pharmaceuticals Inc PHARMACOKINETIC FORMULATIONS OF DEUTERATED BENZOCHINOL INHIBITORS OF THE VESICLE MONOAMINE TRANSPORTER 2
WO2015120317A1 (en) * 2014-02-07 2015-08-13 Neurocrine Biosciences, Inc. Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof

Also Published As

Publication number Publication date
EP3139925B1 (en) 2021-12-01
PL3139925T3 (pl) 2022-03-21
US20170071932A1 (en) 2017-03-16
HUE066361T2 (hu) 2024-07-28
PT3139925T (pt) 2022-01-26
HUE057839T2 (hu) 2022-06-28
PL3936130T3 (pl) 2024-06-10
US20200101063A1 (en) 2020-04-02
KR20250029267A (ko) 2025-03-04
EP3139925A1 (en) 2017-03-15
EP4389227A2 (en) 2024-06-26
KR20200133003A (ko) 2020-11-25
IL248745B (en) 2022-07-01
SMT202400199T1 (it) 2024-07-09
MX387625B (es) 2025-03-18
LT3139925T (lt) 2022-01-25
SI3139925T1 (sl) 2022-04-29
MX2016014429A (es) 2017-04-06
KR20220140647A (ko) 2022-10-18
RU2753740C2 (ru) 2021-08-23
WO2015171802A1 (en) 2015-11-12
CN112741836A (zh) 2021-05-04
KR20160147044A (ko) 2016-12-21
IL248745A0 (en) 2017-01-31
JP2021191799A (ja) 2021-12-16
JP2019218407A (ja) 2019-12-26
CN112741835A (zh) 2021-05-04
US20210196702A1 (en) 2021-07-01
CY1125058T1 (el) 2023-06-09
RS62782B1 (sr) 2022-01-31
SMT202200193T1 (it) 2022-07-21
FI3936130T3 (fi) 2024-04-23
CA2947736C (en) 2023-04-18
LT3936130T (lt) 2024-04-25
JP2017514850A (ja) 2017-06-08
SI3936130T1 (sl) 2024-05-31
JP6635945B2 (ja) 2020-01-29
CN106456629A (zh) 2017-02-22
EP3936130A1 (en) 2022-01-12
CA2947736A1 (en) 2015-11-12
RU2016147523A (ru) 2018-06-08
HRP20240459T1 (hr) 2024-06-21
EP4389227A3 (en) 2024-09-04
ES2976207T3 (es) 2024-07-26
AU2015256012B2 (en) 2020-07-23
HRP20220025T1 (hr) 2022-04-01
DK3936130T3 (da) 2024-03-25
PT3936130T (pt) 2024-04-17
EP3936130B1 (en) 2024-02-14
DK3139925T3 (da) 2021-12-20
JP2024153782A (ja) 2024-10-29
NZ725826A (en) 2023-05-26
AU2015256012A1 (en) 2016-11-24
ES2904526T3 (es) 2022-04-05
RS65359B1 (sr) 2024-04-30
RU2016147523A3 (enExample) 2018-12-28

Similar Documents

Publication Publication Date Title
US20210196702A1 (en) Treatment of hyperkinetic movement disorders
US11000519B2 (en) Pridopidine for treating drug induced dyskinesias
US20080255079A1 (en) Therapeutic Use of Nefopam and Analogues Thereof
US20230355618A1 (en) Raf inhibitor for treating low grade glioma
EP3664787B1 (en) Use of selective serotonin 5-ht1a receptor agonists for treating side-effects of vmat inhibitors
HK40111840A (en) Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders
HK40067005A (en) Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders
JP2019524682A (ja) 抗うつ作用の速い発現のためのボルチオキセチン投与計画
HK40067005B (en) Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders
HK1235303B (en) Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders
HK1235303A1 (en) Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders
US20210275512A1 (en) Pridopidine for treating drug induced dyskinesias
EP2255807A1 (en) Method of treating sleep disorders using the combination of eplivanserin and zolpidem
US20080070952A1 (en) Inhibition or Treatment of Dyskinesia

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20240115

Application number text: 1020227034399

Filing date: 20221004

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240213

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240311

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20240919

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D